Capstone Investment Advisors
CRVS icon

Capstone Investment Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Capstone Investment Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,644
Closed -$40.2K – 1616
2025
Q1 		$40.2K Buy
+12,644
New +$59.6K ﹤0.01% 1300
2021
Q1 		– Sell
-17,776
Closed -$63K – 1721
2020
Q4 		$63K Buy
+17,776
New +$71.6K ﹤0.01% 1606

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's CRVS Position: Q2 2025 in Review

Capstone Investment Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 12,644 shares — an estimated $40.2K sold.

Capstone Investment Advisors first reported a position in CRVS in Q4 2020 and held it in 2 quarters. The position peaked at $63K in Q4 2020. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Capstone Investment Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,644 Corvus Pharmaceuticals shares in Q2 2025, an estimated $40.2K.
  • Capstone Investment Advisors first reported a position in Corvus Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Corvus Pharmaceuticals position peaked at $63K in Q4 2020.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Capstone Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.